Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Licenses Invader, Cleavase to Aclara

NEW YORK, Oct. 16 - Aclara will incorporate with its eTag platform Third Wave Technologies' Invader product and Cleavase enzyme for research use and gene-expression assays, the companies said today.

 

Click here for more information.

 

Separately today, Aclara said that President and CEO Joseph Limber will leave his posts on Dec. 1, and that Sharat Singh has been prooted to senior vice president of the eTag assay technology business.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.